Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Recommendation of “Moderate Buy” by Brokerages

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been given an average rating of “Moderate Buy” by the ten brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $40.8182.

CAPR has been the topic of several recent analyst reports. Industrial Alliance Securities set a $48.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Capricor Therapeutics in a research report on Wednesday, January 14th. Oppenheimer raised their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. UBS Group set a $50.00 target price on Capricor Therapeutics in a research note on Monday, December 15th. Finally, HC Wainwright increased their price target on Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, December 3rd.

Capricor Therapeutics Stock Down 6.0%

NASDAQ:CAPR opened at $23.03 on Friday. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -12.79 and a beta of 0.38. The stock’s 50 day moving average price is $24.82 and its two-hundred day moving average price is $12.96.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). As a group, analysts anticipate that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Trading of Capricor Therapeutics

A number of hedge funds have recently modified their holdings of CAPR. Allworth Financial LP grew its stake in Capricor Therapeutics by 5,021.5% in the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 3,264 shares during the last quarter. Moody Aldrich Partners LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter worth approximately $6,025,000. UBS Group AG grew its position in shares of Capricor Therapeutics by 91.0% in the fourth quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock valued at $6,875,000 after purchasing an additional 113,499 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Capricor Therapeutics by 16.1% during the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock worth $73,936,000 after purchasing an additional 355,161 shares during the period. Finally, GoalVest Advisory LLC bought a new stake in Capricor Therapeutics in the 4th quarter valued at $59,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.